pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
PUBLIC COMPANY
save

$EIKNEikon Therapeutics, Inc.

$EIKN11.05+6.97%
Millbrae, CA, USupdated 4h ago
Website ↗SEC EDGAR ↗Yahoo Finance ↗
community read0 votes
pipeline
2
marketed
0
phase 3
0
catalysts ytd
1
approvals ytd
0
recalls ytd
0

Pipeline(2)

pipeline depth2 products
Phase 2: 2
2Phase 2
Phase 2
IMP-1734
Fallopian Tube Cancer
Phase 2
resiquimod sulfate
Squamous Non-Small Cell Lung Cancer

📅 Upcoming

no upcoming catalysts on record

🕒 Recent(90d)

earnings (1)
Aug 13, 2026
earnings
$EIKN11.05+6.97%
2d ago
Eikon Therapeutics, Inc. earnings
Eikon Therapeutics, Inc.
→
view all catalysts →

Active trials

  • phase3A Safety and Efficacy Study of EIK1001 in Combination With Pembrolizumab and Chemotherapy in Participants With Stage 4 Non-Small Cell Lung Cancer.recruitingn=750
  • phase2A First-in-human Study of PARP1 Selective Inhibitor, IMP1734, in Participants With Advanced Solid Tumorsrecruitingn=156
  • phase2EIK1005-002: A Clinical Research Study Evaluating EIK1005, a Werner Helicase Inhibitor, as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors Including Microsatellite Instability High (MSI-H) Tumorsrecruitingn=160
  • phase1Clinical Study of BDB018: Monotherapy and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumorscompletedn=1
  • phase3Safety and Efficacy of EIK1001 in Combo With Pembro Versus Placebo and Pembro as First-Line Therapy in Patients With Advanced Melanoma.recruitingn=740
  • phase2A Phase 2 Study of EIK1001 in Combo With Pembrolizumab and Chemotherapy in Patients With Stage 4 NSCLCrecruitingn=70
  • phase1BDB001-102: Open Label Dose Escalation of BDB001 in Combination w Atezolizumabcompletedn=40
  • phase2BDB001-201: A Clinical Study of BDB001 in Patients With PD-(L)1 Refractory Solid Tumorscompletedn=1
more trials →

Insider activity

source: SEC Form 4
routine RSU / option mechanics (6)
  • Mar 2, 26grantKlobuchar Michael A · Chief Operating Officer87,157 sh
  • Mar 2, 26grantHuffines Robert Luther · director25,873 sh
  • Mar 2, 26grantFRAZIER KENNETH C · director25,873 sh
  • Mar 2, 26grantPERLMUTTER ROGER M · See remarks268,176 sh
  • Mar 2, 26grantThorner Benjamin Bruno · See Remarks67,044 sh
  • Mar 2, 26grantBaynes Roy D. · Chief Medical Officer134,088 sh
🐶 Hiring Signal
17 open roles at Eikon Therapeutics, Inc. →

Where Eikon Therapeutics, Inc. is staffing up — a leading indicator of pipeline and commercial priorities.

therapeutic areaOncology 4
departmentClinical 4IT & Engineering 2People & Talent 2R&D / Discovery 2Regulatory 2Medical Affairs 1

News

no news has mentioned this company yet
identifiers
ticker
$EIKN
SEC CIK
0001861123
country
US
source
sec_tickers
top tags
Oncology2NSCLC1
mentioned in
0news items
entity-linker matched
Data sources
SEC EDGAR
last refreshed 23m ago
Found something off?
🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?